Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Oruka analysis: ultra-durable psoriasis biologics ORKA-001/002 aim for 1–3 doses/yr with strong efficacy; liquid balance ...

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. The stock rose 8.9% to $9.05 in after-hours trading ...

Doctors in Noida have reported a major advance in psoriasis treatment after a young patient saw near-complete clearance of ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Nimbus Therapeutics has partnered with Eli Lilly in a multi-year agreement to develop AI-driven oral treatments for metabolic diseases. The deal, including potential payments of $1.3 billion, aims to ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

A large US claims analysis links out-of-pocket medication costs with adherence and discontinuation patterns among patients ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...